GlassScriptPhysician profile
William Walter Long
NPI 1356337703
$1,695.62
in general payments reported to CMS, 2019-2025
22 companies · $115 in 2025
The $115 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $66.93 · 2021: $199 · 2022: $275 · 2023: $355 · 2024: $444 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $412.30 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $292.66 | 2021-2025 | Azstarys |
| Sanofi Pasteur INC. | $161.16 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.81 | 2019-2022 | |
| Pfizer INC. | $98.59 | 2019-2021 | |
| Neos Therapeutics, LP | $83.71 | 2019-2024 | Cotempla Xr-Odt |
| Cranial Technologies, INC | $55.54 | 2019-2024 | Doc Band |
| Sobi, INC | $53.15 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $52.85 | 2019-2022 | |
| Rhodes Pharmaceuticals L.P. | $49.39 | 2019 | |
| Ironshore Pharmaceuticals INC. | $48.25 | 2024 | |
| Kaleo, INC. | $46.41 | 2022-2024 | Auvi-Q |
| Collegium Pharmaceutical, INC. | $39.43 | 2025 | Jornay Pm |
| Organon LLC | $29.36 | 2023-2025 | Nexplanon |
| Vertical Pharmaceuticals, LLC | $22.28 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.37 | 2023 | |
| Verrica Pharmaceuticals INC. | $19.25 | 2024 | Ycanth |
| Ars Pharmaceuticals Operations, INC. | $16.45 | 2025 | Neffy |
| Phadia US INC. | $14.50 | 2022 | |
| Glaxosmithkline, LLC. | $14.42 | 2024 | Bexsero |
| Teva Pharmaceuticals USA, INC. | $13.86 | 2019 | |
| Shire North American Group INC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.